Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.
Benign prostatic hyperplasia
Minimally invasive
Rezūm
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
23
11
2020
accepted:
18
02
2021
pubmed:
1
4
2021
medline:
19
1
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
Rezūm is the latest developed minimally invasive treatment for benign prostatic hyperplasia (BPH). We aimed to carefully assess the functional outcomes of patients treated with Rezūm for BPH. We prospectively followed 135 consecutive patients treated by Rezūm at 5 institutions from June 2019 to August 2020. The International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-UI SF), the Overactive Bladder Questionnaire-Short Form (OAB-q SF) score, the International Index of Erectile Function (IIEF-5) and questions 9 and 10 to assess ejaculatory dysfunction were recorded. Election criteria were age > 18, no prior prostate interventions, IPSS ≥ 13, post-void residual ≤ 250 mL, prostate volume between 30 and 120 cc. The median operative time was 10.5 (IQR 8.7-15) min. All patients were dismissed few hours after surgery with indwelling urinary catheter that was removed after a median of 7 (IQR 7-10) days. A significantly decrease of IPSS from baseline at first (p = 0.001) and third (p < 0.0001) month after surgery was reported. No difference was reported in terms of ICIQ-UI SF score postoperatively. A mild reduction of the OAB-q SF score was reported at 1 month from surgery (p = 0.06) that turned significant at 3 months postoperatively (p < 0.0001). A slight but statistically significant increase of the IIEF-5 score was reported from baseline at 6 months (p = 0.04). Postoperatively, patients reported a significantly decrease of ejaculatory dysfunction after alpha-blocker interruption. Rezūm treatment is a feasible minimally invasive option for patients with BPH symptoms and showed optimal early functional outcomes.
Identifiants
pubmed: 33787986
doi: 10.1007/s00345-021-03642-4
pii: 10.1007/s00345-021-03642-4
pmc: PMC8010783
doi:
Substances chimiques
Steam
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3875-3880Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Issa MM, Fenter TC, Black L et al (2006) An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12:S83-89
pubmed: 16551206
Campbell FM, Walsh PC (2002) Urology, 8th edn. Saunders, pp 1297–1336
Lee SWH, Chan EMC, Lai YK (2017) The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep 7:7984. https://doi.org/10.1038/s41598-017-06628-8
doi: 10.1038/s41598-017-06628-8
pubmed: 28801563
pmcid: 5554261
Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int 97(Suppl 2):3–6. https://doi.org/10.1111/j.1464-410X.2006.06097.x (discussion 21-22)
doi: 10.1111/j.1464-410X.2006.06097.x
pubmed: 16507045
Cindolo L, Pirozzi L, Fanizza C et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418–425. https://doi.org/10.1016/j.eururo.2014.11.006
doi: 10.1016/j.eururo.2014.11.006
pubmed: 25465970
Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR (2019) The Rezūm system–a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol 26:9787–9793
pubmed: 31180311
McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled Study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041
doi: 10.1016/j.urology.2018.12.041
pubmed: 30677455
Suzuki T, Otsuka A, Ozono S (2016) Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 23:929–933. https://doi.org/10.1111/iju.13188
doi: 10.1111/iju.13188
pubmed: 27545297
Green Z, Westwood J, Somani BK (2019) What’s new in rezum: a transurethral water vapour therapy for BPH. Curr Urol Rep 20:39. https://doi.org/10.1007/s11934-019-0903-7
doi: 10.1007/s11934-019-0903-7
pubmed: 31152253
Zlotta AR, Giannakopoulos X, Maehlum O et al (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44:89–93. https://doi.org/10.1016/s0302-2838(03)00218-5
doi: 10.1016/s0302-2838(03)00218-5
pubmed: 12814680
Mattiasson A, Wagrell L, Schelin S et al (2007) Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 69:91–96. https://doi.org/10.1016/j.urology.2006.08.1115 (discussion 96-97)
doi: 10.1016/j.urology.2006.08.1115
pubmed: 17270624
Mynderse LA, Roehrborn CG, Partin AW et al (2011) Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 185:1804–1810. https://doi.org/10.1016/j.juro.2010.12.054
doi: 10.1016/j.juro.2010.12.054
pubmed: 21420115
Roehrborn CG, Barkin J, Gange SN et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24:8802–8813
pubmed: 28646935
Misrai V, Rijo E, Zorn KC et al (2019) Waterjet ablation therapy for treating benign prostatic obstruction in patients with small- to medium-size glands: 12-month results of the first French aquablation clinical registry. Eur Urol 76:667–675. https://doi.org/10.1016/j.eururo.2019.06.024
doi: 10.1016/j.eururo.2019.06.024
pubmed: 31281024
Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7:13–18. https://doi.org/10.2147/RRU.S74040
doi: 10.2147/RRU.S74040
pubmed: 25674555
pmcid: 4321608
Mynderse LA, Hanson D, Robb RA et al (2015) Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86:122–127. https://doi.org/10.1016/j.urology.2015.03.021
doi: 10.1016/j.urology.2015.03.021
pubmed: 25987496
McVary KT, Gange SN, Gittelman MC et al (2016) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 195:1529–1538. https://doi.org/10.1016/j.juro.2015.10.181
doi: 10.1016/j.juro.2015.10.181
pubmed: 26614889
Jones P, Rajkumar GN, Rai BP et al (2016) Medium-term outcomes of urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 97:20–24. https://doi.org/10.1016/j.urology.2016.05.003
doi: 10.1016/j.urology.2016.05.003
pubmed: 27208817
Jones P, Rai BP, Nair R, Somani BK (2015) Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology 86:676–681. https://doi.org/10.1016/j.urology.2015.05.011
doi: 10.1016/j.urology.2015.05.011
pubmed: 26238328
Taktak S, Jones P, Haq A et al (2018) Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Ther Adv Urol 10:183–188. https://doi.org/10.1177/1756287218760518
doi: 10.1177/1756287218760518
pubmed: 29899759
pmcid: 5993070
Roehrborn CG, Teplitsky S, Das AK (2019) Aquablation of the prostate: a review and update. Can J Urol 26:20–24
pubmed: 31481145
Johnston MJ, Noureldin M, Abdelmotagly Y et al (2020) Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int. https://doi.org/10.1111/bju.15203
doi: 10.1111/bju.15203
pubmed: 32777175
Rocco B, Sighinolfi MC, Sandri M et al (2020) The dramatic COVID 19 outbreak in Italy is responsible of a huge drop of urological surgical activity: a multicenter observational study. BJU Int. https://doi.org/10.1111/bju.15149
doi: 10.1111/bju.15149
pubmed: 32558053
pmcid: 7322984
Gratzke C, Barber N, Speakman MJ et al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119:767–775. https://doi.org/10.1111/bju.13714
doi: 10.1111/bju.13714
pubmed: 27862831
Reale G, Marchioni M, Altieri V et al (2020) Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urol Nefrol 72:622–628. https://doi.org/10.23736/S0393-2249.20.03597-3
doi: 10.23736/S0393-2249.20.03597-3
pubmed: 32284526